SCHEMBL936788

SCHEMBL936788

CC(C)NC(=O)c1cccc(-c2cc(-c3ccc(OCCN(C)C)cc3)[nH]n2)c1

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PRKD1 Q15139 13/20 0.65
RET P07949 2/20 0.51
KDR P35968 1/20 0.46
ROCK2 O75116 1/20 0.45
LIMK1 P53667 1/20 0.45
NPC1 O15118 1/20 0.44
TP53 P04637 1/20 0.44
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.44
HTT P42858 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
HRH3 Q9Y5N1 1/20 0.44
ADORA3 P0DMS8 1/20 0.44
ADORA2A P29274 1/20 0.44
ADORA2B P29275 1/20 0.44
ADORA1 P30542 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6924065 0.95 PRKD1 (0.64) PRKD1RETKDRHRH3ADORA3
SCHEMBL1079502 0.90 PRKD1 (0.70) PRKD1NPC1TP53GAAMAPT
SCHEMBL1053391 0.86 PRKD1 (0.70) PRKD1NPC1TP53GAAMAPT
SCHEMBL960488 0.86 PRKD1 (0.70) PRKD1NPC1TP53GAAMAPT
SCHEMBL6924052 0.86 PRKD1 (0.69) PRKD1ADORA3ADORA2AADORA2BADORA1
SCHEMBL962069 0.84 PRKD1 (0.66) PRKD1RETKDR
SCHEMBL937410 0.84 PRKD1 (0.81) PRKD1ADORA3ADORA2AADORA2BADORA1
SCHEMBL6923756 0.83 PRKD1 (0.66) PRKD1NPC1TP53GAAMAPT
SCHEMBL1024920 0.82 PRKD1 (0.64) PRKD1NPC1TP53GAAMAPT
SCHEMBL936452 0.81 PRKD1 (0.74) PRKD1ADORA3ADORA2AADORA2BADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011009484-A1 ARYLPYRAZOLES AND ARYLISOXAZOLES AND THEIR USE AS PKD MODULATORS NOVARTIS AG (CH) 2011-01-27 WO disclosed
WO-2011009484-A1 ARYLPYRAZOLES AND ARYLISOXAZOLES AND THEIR USE AS PKD MODULATORS NOVARTIS AG (CH) 2011-01-27 WO disclosed